Monro initiates strategic alternatives review; Q4 sales down 7.2%, operating loss narrows

MONRO, INC.

Board to evaluate asset sales, refinancing, acquisitions, or sale of Company; no definitive timeline.
Q4 sales $273.8M, down 7.2% YoY; comparable store sales decreased 2.4%.
Gross margin expanded 90 bps to 34.2%; operating loss $5.2M vs $23.8M loss in prior year quarter.
Declared Q1 FY2027 dividend of $0.28/share, payable June 16, 2026 to holders of record June 2.

item 2.02 item 7.01 item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-26-240509
form_type: 8-K
ticker: MNRO
cik: 0000876427
company_name: MONRO, INC.
filed_at: 2026-05-27T11:44:18+00:00
discovered_at: 2026-05-27T11:45:00.326396+00:00
generated_at: 2026-05-27T11:46:56.069821+00:00
sec_items: ["2.02", "7.01", "8.01", "9.01"]
event_type: other_material
sentiment: neutral
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-26-240509
json_url: https://secwatch.observer/filing/0001193125-26-240509.json
markdown_url: https://secwatch.observer/filing/0001193125-26-240509.md
text_url: https://secwatch.observer/filing/0001193125-26-240509.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/876427/000119312526240509/0001193125-26-240509-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/876427/000119312526240509/d128639d8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Comparable filings

OPTU

Optimum raises $500M via preferred units, starts $300M tender at $2.50 to shield assets from CSC debt

Optimum Communications, Inc. June 1, 2026, 8:16 AM ET other_material Items 1.01, 3.02, 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

NXTC

NextCure Phase 1 SIM0505 data: 55% ORR in gynecologic cancers; cash into Q1 2027

NextCure, Inc. June 1, 2026, 8:10 AM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

JBIO

Jade Biosciences reports Phase 1 interim data: JADE101 shows ~70% IgA reduction, favorable safety, differentiated PK

Jade Biosciences, Inc. June 1, 2026, 7:55 AM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

EIKN

Eikon reports 63.1% ORR in Phase 2 NSCLC trial of EIK1001; PARP1 inhibitor EIK1003 shows 24.5% ORR with paclitaxel

Eikon Therapeutics, Inc. June 1, 2026, 7:30 AM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

MDAI

Spectral AI gets FDA clearance for DeepView burn indication; targets first commercial sales by year-end 2026

Spectral AI, Inc. June 1, 2026, 4:01 PM ET other_material Items 5.07, 7.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

GPRO

GoPro refiles financials with going-concern warning; potential defaults on debt

GoPro, Inc. June 1, 2026, 9:12 AM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

LIXT

Lixte Biotechnology pivots to AI energy infrastructure; appoints Denham Capital founder to board

LIXTE BIOTECHNOLOGY HOLDINGS, INC. June 1, 2026, 8:55 AM ET other_material Items 5.02, 7.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

TTRX

Turn Therapeutics GX-03 Phase 2 interim: 92.6% EASI-50 at 4 weeks; no SAEs

Turn Therapeutics Inc. June 1, 2026, 8:45 AM ET other_material Items 7.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

Source: SEC EDGAR

accession 0001193125-26-240509

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.